Faecal Microbiota Transplantation (FMT) in Patients With IBSmechanism(s) of Action

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

186 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-03

Study Completion Date

2022-03-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Two hundrad patients are randomized to either 90 g transplant, 90 g transplant twice with 1week interval into the distal small intestine via working channel of a gastroscope, or to 90 g transplant into the coecum of the colon via working channel of a colonoscope. The patients shall complete 5 questionnaires measuring symptoms, fatigue and quality of life and collect a feces sample at the baseline, and at 3, 6 and 12 months after FMT. Dysbiosis and fecal bacterial are determined by using 16S rRNA gene.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Donor Selection for Faecal Microbiota Transplantation in Irritable Bowel Syndrome

NCT06171126

Irritable Bowel Syndrome

ACTIVE_NOT_RECRUITING NA

Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome

NCT02092402

Irritable Bowel Syndrome (IBS)

COMPLETED NA

Fecal Transplantation in Patients With IBS

NCT03333291

IBS - Irritable Bowel Syndrome

COMPLETED NA

FMT in the Treatment of IBS

NCT03561519

Irritable Bowel Syndrome

COMPLETED NA

Donor Versus Autologous Fecal Microbiota Transplantation for Irritable Bowel Syndrome

NCT04691544

Irritable Bowel Syndrome

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients Two hundrad patients who fulfil Rome IV criteria for irritable bowel syndrome (IBS) shall be included in the study. All the IBS subtypes shall be included.

Donor Investigators are going to use the same super-donor they used in their previous randomised double-blind, placebo-controlled study. The donor is athletic Caucasian man aging 36 years. He is non-smoker and is completely healthy without any medication and with a BMI of 23.5. He is not relative to any of the patients in the trial. He was borne by vaginal delivery and breastfeed. He was treated 3 times with antibiotics during his life. He trains 5 times weekly an hour each time. He took regularly dietary supplements rich in proteins, vitamins, fibres and minerals that made his diet richer than average in these substances. He was screened according to the guidelines for donors for FMT. Before he was accepted as a donor the microbiota was analysed in a faecal sample using GA-map Dysbiosis test. The analysis revealed a dysbiosis index (DI)= 1, indicating normobiosysis. In addition, he had excess of bacteria belonging to the Firmicutes. His faeces shall be tested every third moth during the trial.

Protocol

The patients are randomized to either 90 g transplant, 90 g transplant twice with 1week interval into the distal small intestine, or to 90 g transplant into the coecum of the colon. The patients shall complete 5 questionnaires and deliver fecal samples at the baseline, and at 3 , 6 , and 12 months after FMT.

Faeces collection, preparation and administration Faeces from both the donor and patients shall be collected and stored at - 80•. Frozen faeces shall be thawed and each 30 g is dissolved in 30 mL of 0.9% sterile saline. The dissolved stool administrated to the patients, after overnight fast, through working channel of gastroduodeno-scope in pars descendent duodenum distal to the papilla of Vater or to the coecum through working channel of a colonoscope.

Analysis Questionnaires

1. IBS symptom severity Scale (IBS-SSS).
2. Birmingham Symptom scale.
3. IBS-quality of life (IBSQo) Questionnaire.
4. Short form of Nepean Dyspepsia Index (SF-NDI).
5. Fatigue Assessment Scale (FAS).

Microbiome analysis Gut microbiota analysis is performed using the Genetic analysis-mapTM Dysbiosis test (Genetic Analysis AS, Oslo, Norway) by algorithmically assessing faecal bacterial abundance and profile (dysbiosis index, DI), and potential deviation in the microbiome from normobiosis. GA-map test is based on faecal homogenization, mechanical bacterial cell disruption and automated total bacterial genomic DNA extraction using magnetic beads. DI is based on 54 DNA probes targeting more than 300 bacterial strains based on their 16S rRNA sequence in seven variable regions (V3-V9). Twenty-six bacteria probes are species specific, 19 detect bacteria on genus level, and 9 probes detect bacteria at higher taxonomic levels. Probe labelling is by single nucleotide extension and hybridization to complementary probes coupled to magnetic beads, and signal detection by using BioCode 1000A 128-Plex Analyser (Applied BioCode, Santa Fe Springs, CA, USA). A DI above 2 shows a microbiota profile that differs from that of the normobiotic reference collection (DI 1-2: non-dysbiosis, DI: moderate, DI 4-5: severe dysbiosis).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Smal intestine once

90-g fecal transplant given into the small intestine once.

Group Type ACTIVE_COMPARATOR

Feces

Intervention Type DIETARY_SUPPLEMENT

Feces from healthy donor

Small intestine twice

90-g fecal transplant given into the small intestine twice with 1 week interval.

Group Type ACTIVE_COMPARATOR

Feces

Intervention Type DIETARY_SUPPLEMENT

Feces from healthy donor

Large intestine once

90-g fecal transplant given into the large intestine once.

Group Type ACTIVE_COMPARATOR

Feces

Intervention Type DIETARY_SUPPLEMENT

Feces from healthy donor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Feces

Feces from healthy donor

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who fulfil Rome IV criteria for the diagnosis of IBS.
2. Patients were investigated to exclude other gastrointestinal organic cause(s).
3. Moderate-to-severe IBS symptoms, as indicated by a score of ≥175 on the IBS Severity Scoring System (IBS-SSS).

Exclusion Criteria

1. Pregnant or lactating women.
2. The use of antibiotics or probiotics within 1 month prior to FMT.
3. Immunocompromised patients defined as those treated by immune- suppressive medications.
4. Patients with co-morbidity such as kidney failure or chronic heart disease.
5. System disease such as diabetes.
6. Patients with serious psychiatric disorders or drug abuse.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No